Immunomedics is launching a registrational Phase 3 study for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer, after failure of at least 2, and no more than 4, prior chemotherapy regimens for metastatic disease. For more information on this clinical trial, please visit TROPiCS-02
Immunomedics is launching a Phase 2 open label study of sacituzumab govitecan in patients with advanced solid tumors. For more information on this clinical trial, please visit TROPiCS-03
Immunomedics is currently sponsoring an international Phase 3 clinical trial of sacituzumab govitecan in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease. For more information on this clinical trial, please visit tnbctrial.com
Immunomedics is recruiting for a Phase 2 trial of sacituzumab govitecan for patients with metastatic (Stage IV) urothelial cancer after failure of a platinum-based regimen and/or anti-PD-1/PD-L1 based therapies. For more information visit TrophyTrials.com
Compassionate Use Program
Immunomedics does not have a Compassionate Use Program for IMMU-132 at this time; however, patients with refractory/relapsed triple-negative breast cancer may be eligible for enrollment in the large ASCENT clinical trial (ClinicalTrial.gov Identifier: NCT02574455). Subjects are currently being recruited at 177 locations in the United States and Europe.